NCT01608009

[18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer

Phase 1b Exploratory Study of [18F]Fluciclatide-PET as a Marker of Angiogenic Response to Combination Therapy With the Pan-VEGF Inhibitor, Pazopanib, and Weekly Paclitaxel in Platinum Resistant Ovarian Cancer

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Imperial College London · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess \[18F\] -fluciclatide as a biomarker of response to pazopanib and to evaluate the efficacy and safety of the combination of pazopanib and paclitaxel in platinum-resistant ovarian cancer patients.

Conditions

• Ovarian Neoplasm

Interventions

Type	Name	Description
DRUG	Pazopanib and paclitaxel	Pazopanib 800mg od for 7 days, followed by 18 weeks of combination therapy (paclitaxel 80mg/m2 weekly and pazopanib 800mg od). Following the completion of combination therapy, patients will continue on maintenance pazopanib 800mg od until disease progression.

Timeline

• Start date: 2012-07-01
• Primary completion: 2015-05-01
• Completion: 2016-04-01
• First posted: 2012-05-30
• Last updated: 2017-03-10

Locations

2 sites across 1 country: United Kingdom